Trials / Unknown
UnknownNCT05312268
Rasburicase Treatment in Chronic Gouty Arthritis
Efficacy and Safety of Rasburicase in the Treatment of Chronic Gouty Arthritis: A Multicenter Randomized Controlled Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study will establish efficacy and safety of rasburicase in chronic gouty arthritis
Detailed description
The study hypothesis is that the proportion of patients who achieved the primary endpoint after 12 weeks of treatment with rasburicase combined with oral urate-lowering therapy is superior to 12 weeks of treatment with oral urate-lowering therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasburicase | Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times. |
Timeline
- Start date
- 2022-06-15
- Primary completion
- 2024-10-15
- Completion
- 2025-04-15
- First posted
- 2022-04-05
- Last updated
- 2023-05-09
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05312268. Inclusion in this directory is not an endorsement.